Actinium News

Actinium Announces Announced Five Abstracts Accepted For Presentation At 2024 SNMMI Annual Meeting

- Iomab-B and Actimab-A are the only targeted radiotherapies in for acute myeloid leukemia addressing different parts of the patient journey- Improved survival demonstrated with both Iomab

BenzingaMay 13 07:38

Actinium Announces Multiple Abstracts Highlighting Its Antibody Radiation Conjugates Iomab-B and Actimab-A and Novel Linker Technology for Solid Tumors Accepted for Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs)...

PR NewswireMay 13 07:30

Actinium Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial With Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs)...

PR NewswireMay 7 07:00

NYSE American Net Change Percentage Gainers & Losers

GAINERS COMPANY SYMBOL LAST CHANGE PERCENT VOLUME ------- ------ ---- ------ ------- ------ NFT

Dow JonesMay 2 16:39

Radiopharma Stocks Higher as Sector Welcomes the Latest M&A Deal

Seeking AlphaMay 2 13:31

HC Wainwright & Co. : Actinium Pharma (ATNM.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $50.00.

HC Wainwright & Co. : Actinium Pharma (ATNM.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $50.00.

Zhitong FinanceApr 29 05:10

Actinium Says Phase 3 SIERRA Trial Results Of Iomab-B Shows Improving OS For AML Patients

RTTNewsApr 18 08:33

Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients With Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting

-- Iomab-B led bone marrow transplant produced high rates of complete remission and durable complete remission regardless of TP53 mutation status in patients age 55 and above with high-risk active re

PR NewswireApr 18 07:00

Wall Street Bulls Eye a 290% Upside on Actinium Pharmaceuticals, Inc. Amidst Groundbreaking Cancer Therapy Innovations

EvertiseApr 1 12:42

Analysts Offer Insights on Healthcare Companies: Actinium Pharmaceuticals (ATNM) and Centessa Pharmaceuticals (CNTA)

TipRanksApr 1 09:20

Actinium's Phase 3 Trial Results Show Survival Benefit In Acute Myeloid Leukemia Patients; Stock Up

RTTNewsApr 1 09:04

Actinium Pharmaceuticals Price Target Maintained With a $21.00/Share by Cantor Fitzgerald

Actinium Pharmaceuticals Price Target Maintained With a $21.00/Share by Cantor Fitzgerald

Dow JonesApr 1 07:32

Cantor Fitzgerald Reiterates Overweight on Actinium Pharma, Maintains $21 Price Target

Cantor Fitzgerald analyst Kristen Kluska reiterates Actinium Pharma (AMEX:ATNM) with a Overweight and maintains $21 price target.

BenzingaApr 1 07:24

Analysts Offer Insights on Healthcare Companies: Altimmune (ALT), Kiora Pharmaceuticals (KPRX) and Actinium Pharmaceuticals (ATNM)

TipRanksMar 28 06:30

HC Wainwright & Co. Reiterates Buy on Actinium Pharma, Maintains $50 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Actinium Pharma (AMEX:ATNM) with a Buy and maintains $50 price target.

BenzingaMar 26 11:14

Actinium Pharma Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/26/2024 498.8% HC Wainwright & Co. → $50 Reiterates Buy → Buy 03/19/2024 259.28% Maxim Group $20 → $30

BenzingaMar 26 11:13

Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning With Leading FDA Approved Commercial CAR T-Cell Therapy

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced that the Un

BenzingaMar 26 06:21

Full-Life Technologies Erreicht Behördlichen Meilenstein Mit Nuklearer Genehmigung Und Treibt Den Bau Einer Radioisotopenanlage Voran

GEMBLOUX, Belgien, 26. März 2024 /PRNewswire/ -- Full-Life Technologies („Full-Life") gab heute bekannt, dass seine Tochtergesellschaft „Full-Life Technology Europe" vor kurzem von der belgischen Fo

PR NewswireMar 25 19:00

Full-Life Technologies Achieves Regulatory Milestone With Nuclear Permit, Advancing Radioisotope Facility Construction

GEMBLOUX, Belgium, March 25, 2024 /PRNewswire/ -- Full-Life Technologies ("Full-Life"), today announced the recent achievement of its subsidiary "Full-Life Technology Europe" has obtained a Nuclear P

PR NewswireMar 25 19:00

Earnings Week Ahead: Walgreens Boots Alliance, Carnival, GameStop and More

Seeking AlphaMar 24 07:01